17.(amended) An isolated polypeptide or protein comprising a polypeptide as claimed in claim 1, wherein the amino acid sequence of said isolated polypeptide or protein is not that set out in either of SEQ. ID. NOs. 1 and 2 or that coded for by nucleotides 334-918 of SEQ. ID. NO. 7.

19.(amended) An isolated nucleic acid molecules comprising a nucleotide sequence coding for a polypeptide or protein as claimed in claim 4, or a complementary nucleotide sequence, wherein said nucleotide sequence is not that set out in any of SEQ. ID. NOs. 3, 4, 5, 6 or 7.

26.(amended) A polypeptide binding agent which selectively binds or is specific for an isolated polypeptide or protein as claimed in claim 4.

27.(amended) A polypeptide binding agent as claimed in claim 26, comprising an antibody, preferably a monoclonal antibody or an antibody fragment.

28.(amended) A polypeptide binding agent which selectively binds or is specific for a complex of a polypeptide as claimed in claim 4 and a major histocompatibility complex molecule type HLA-A2, preferably HLA-A2.1, but which does not bind said major histocompatibility complex molecule alone.

29.(amended) A polypeptide binding agent as claimed in claim 28, comprising a cytolytic T-cell.

31.(amended) A pharmaceutical composition for the prophylaxis, therapy or diagnosis of tumours comprising a polypeptide or protein as claimed in claim 11, optionally in admixture with a pharmaceutically acceptable carrier and optionally further comprising a major histocompatibility complex molecule type HLA-A2, preferably HLA-A2.1.

32.(amended) A pharmaceutical composition for the prophylaxis, therapy or diagnosis of tumours comprising a polypeptide or protein as claimed in claim 11, complexed with a major histocompatibility complex molecule, HLA, and presented on the surface of an APC, preferably a dendritic cell, wherein said complex is formed by pulsing said APC with polypeptide or protein.

Cont B6

33.(amended) A cell, preferably an APC, and more preferably, a dendritic cell, which has been pulsed with a polypeptide or protein as claimed in claim 11 to present on its surface said polypeptide or protein as a complex with a major histocompatibility complex molecule, HLA.

B7

35.(amended) A method of diagnosing disease, preferably cancer, comprising contacting a biological sample isolated from a subject with an agent that is specific for a polypeptide or protein as claimed in claim 11, and assaying for interaction between the agent and the polypeptide or protein, either free in or forming an integral part of the sample as a determination of the disease.

B8

37.(amended) A method of producing a cytolytic T-cell culture reactive against tumour cells, comprising removing a lymphocyte sample from an individual and culturing the lymphocyte sample with a polypeptide or protein as claimed in claim 11.

38.(amended) A product comprising T-cells reactive against a tumour cell expressing an antigen comprising a polypeptide or protein as claimed in claim 11, for use in the prophylaxis, therapy, or diagnosis of tumours.

Please add the following new claim.

B9

41. A method of diagnosing disease, preferably cancer, comprising contacting a biological sample isolated from a subject with an agent that is specific for a nucleic acid molecule as claimed in claim 19 and assaying for interaction between the agent and the nucleic acid molecule either free in or forming an integral part of the sample as a determination of the disease.

Remarks

Applicants have canceled and amended claims to reduce filing fees and to bring the claims into compliance with United States rules. No new matter has been added. A copy of the amended claims, marked up to indicate insertions (underline) and deletions (brackets) is attached hereto on separate pages.

Applicants respectfully request that the Examiner base examination upon the claims as amended in the international stage and as amended herewith.

In view of the foregoing amendments, favorable action is respectfully requested. The Examiner is invited to contact the undersigned to advance the prosecution in any respect.

Respectfully submitted,

John R. Van Amsterdam
Reg. No. 40,212
WOLF, GREENFIELD & SACKS, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210
Tel: (617) 720-3500

Attorney's Docket No. L0461/7115
Dated: September 4, 2001
xNDD

Amended Claims:

4.(amended) A nonapeptide as claimed in [either of] claim [3 and] 4, wherein the amino acid in position 3 is Y and/or the amino acid in position 4 is D and/or the amino acid in position 5 is G and/or the amino acid in position 7 is E and/or the amino acid in position 8 is H.

11.(amended) An isolated polypeptide of up to about 93 amino acids in length, characterised by comprising a nonapeptide [or decapeptide] as claimed in [any of] claim[s 3-10] 4.

17.(amended) An isolated polypeptide or protein comprising a polypeptide as claimed in [any of] claim[s] 1[-16], wherein the amino acid sequence of said isolated polypeptide or protein is not that set out in either of SEQ. ID. NOs. 1 and 2 or that coded for by nucleotides 334-918 of SEQ. ID. NO. 7.

19.(amended) An isolated nucleic acid molecules comprising a nucleotide sequence coding for a polypeptide or protein as claimed in [any of] claim[s 1-17] 4, or a complementary nucleotide sequence, wherein said nucleotide sequence is not that set out in any of SEQ. ID. NOs. 3, 4, 5, 6 or 7.

26.(amended) A polypeptide binding agent which selectively binds or is specific for an isolated polypeptide or protein as claimed in [any of] claim[s 1-18] 4.

27.(amended) A polypeptide binding agent as claimed in claim 26, comprising an antibody, preferably a monoclonal antibody or an antibody fragment [specific for an isolated polypeptide or protein as claimed in any of claims 1-18].

28.(amended) A polypeptide binding agent [as claimed in claim 26 or claim 27] which selectively binds or is specific for a complex of a polypeptide as claimed in [any of] claim[s 1-18] 4 and a major histocompatibility complex molecule type HLA-A2, preferably HLA-A2.1, but which does not bind said major histocompatibility complex molecule alone.

29.(amended) A polypeptide binding agent as claimed in [any of] claim[s 26-]28, comprising a cytolytic T-cell [which is specific for a complex of a polypeptide as claimed in any of claims 1-18 and a major histocompatibility complex molecule type HLA-A2, preferably HLA-A2.1].

31.(amended) A pharmaceutical composition for the prophylaxis, therapy or diagnosis of tumours comprising a polypeptide or protein as claimed in [any of] claim[s 1-18] 11, [a nucleic acid molecule as claimed in any of claims 19-21, an expression system as claimed in either of claims 22 or 23, a host cell as claimed in either of claims 24 or 25, or a polypeptide binding agent as claimed in any of claims 26-29,] optionally in admixture with a pharmaceutically acceptable carrier and optionally further comprising a major histocompatibility complex molecule type HLA-A2, preferably HLA-A2.1.

32.(amended) A pharmaceutical composition for the prophylaxis, therapy or diagnosis of tumours comprising a polypeptide or protein as claimed in [any of] claim[s 1-18] 11, complexed with a major histocompatibility complex molecule, HLA, and presented on the surface of an APC, preferably a dendritic cell, wherein said complex is formed by pulsing said APC with polypeptide or protein.

33.(amended) A cell, preferably an APC, and more preferably, a dendritic cell, which has been pulsed with a polypeptide or protein as claimed in [any of] claim[s 1-18] 11 to present on its surface said polypeptide or protein as a complex with a major histocompatibility complex molecule, HLA.

35.(amended) A method of diagnosing disease, preferably cancer, comprising contacting a biological sample isolated from a subject with an agent that is specific for a polypeptide or protein as claimed in [any of] claim[s 1-18] 11, [or a nucleic acid molecule as claimed in any of claims 19-21] and assaying for interaction between the agent and [any of] the polypeptide[,] or protein, [or nucleic acid molecule] either free in or forming an integral part of the sample as a determination of the [disorder] disease.

37.(amended) A method of producing a cytolytic T-cell culture reactive against tumour cells, comprising removing a lymphocyte sample from an individual and culturing the lymphocyte sample with a polypeptide or protein as claimed in [any of] claim[s 1-15] 11[, an expression vector as claimed in either of claims 22 or 23, a host cell as claimed in either of claims 24 or 25].

38.(amended) A product comprising T-cells reactive against a tumour cell expressing an antigen comprising a polypeptide or protein as claimed in [any of] claim[s 1-18] 11, for use in the prophylaxis, therapy, or diagnosis of tumours.